Press Releases
GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test
New York, New York July 26, 2021 GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today […]
GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology
New York, NY, July 8, 2021 –GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it […]
Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick’ Alternative in Global Glucose Monitoring Survey
Global results show 90% of patients are in favor of a saliva-based glucose test New York, NY, June 7, 2021 – GBS Inc. (Nasdaq: GBS), a life sciences company developing […]
GBS Inc. Reports First Quarter 2021 Financial Results and Recent Business Highlights
• Anticipate Emergency Use Submission for SARS-CoV-2 Antibody Biosensor Test in the Second Half of 2021.• $14 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2021, […]
GBS, Inc. receives approval to commence validation clinical study for rapid SARS-CoV-2 diagnostic test
NEW YORK APRIL 15, 2021 — GBS, Inc. (GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for Biologically Inspired Engineering at Harvard […]
GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests
New York, NY, February 18, 2021 – GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary […]
Harvard’s Wyss Institute collaborates with GBS Inc. on the Wyss’ eRapid-based COVID-19 diagnostic to help curb the pandemic
Combination of the Wyss’ electrochemical sensing technology with GBS’s transistor technology could enable fast, multiplexed, low-cost COVID-19 biomarker analysis in point-of-care applications This article has been republished with permission from […]
FDA Engagement Commences for Saliva Glucose Biosensor in the US
SYDNEY – May 6, 2020 The iQ Group Global is pleased to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD) has commenced engagement with the US Food and Drug […]
The iQ Group Global Partners with Harvard University for Real-Time, Printable COVID-19 Diagnostic Test
SYDNEY – May 29, 2020 The iQ Group Global has announced a collaboration with Harvard University to develop a printable point-of-care SARS-CoV-2 antibody test for the COVID-19 disease that could […]
The iQ Group Global Introduces the Saliva Glucose Biosensor
The world’s first non-invasive, saliva-based glucose test for diabetes management SYDNEY – February , 2019 – The iQ Group Global, a consortium of life science and financial services companies which […]
